



CANNON BUILDING
861 SILVER LAKE BLVD., SUITE 203
DOVER, DELAWARE 19904-2467

STATE OF DELAWARE
BOARD OF PHARMACY

TELEPHONE: (302) 744-4500
FAX: (302) 739-2711
WEBSITE: DPR.DELAWARE.GOV
EMAIL: customerservice.dpr@state.de.us

PUBLIC MEETING NOTICE:	BOARD OF PHARMACY – Legislative Committee Meeting
DATE AND TIME:	Wednesday, October 19, 2016 9:30 am
PLACE:	Conference Room A., 2 nd Floor Cannon Building 861 Silver Lake Blvd., Dover, DE 19904
APPROVED:	Approved November 16, 2017

MEMBERS PRESENT

Hooshang Shanehsaz, Chair
Susan Esposito, R.Ph.
Bonnie Wallner, R.Ph.
Kim Robbins, R.Ph.
Tejal Patel, PharmD
Jay Galloway

MEMBERS ABSENT

David Dryden, R.Ph., J.D., Pharmacy Executive Director

ALSO PRESENT

Ron Phillips
Dr. Bob Thompson
Cheryl Heiks

DIVISION STAFF/DEPUTY ATTORNEY GENERAL PRESENT

Eileen Kelly, Deputy Attorney General
Christine Mast, Administrative Specialist III

CALL TO ORDER

Mr. Shanehsaz called the meeting to order at 11:56 am.

REVIEW OF MINUTES

A motion was made by Ms. Esposito and seconded by Mr. Galloway to approve the meeting minutes for April 20, 2016. The motion carried.

A motion was made by Ms. Esposito and seconded by Ms. Patel to approve the meeting minutes for August 17, 2016. The motion carried.

UNFINISHED BUSINESS

A motion to move ahead to agenda item; IV.A., was made by Ms. Esposito seconded by Ms. Patel. The motion carried.

FDA Veterinary Compounding Regulation 5.1.7.1 – Ms. Kelly stated that she attended the FDA Compounding meeting for assistance with this issue. She stated that states across the country are trying to make sense of

the correct and most appropriate way to handle veterinary compounding. The FDA is currently working towards the final regulations changes. Ms. Kelly provided the committee some information from surrounding states approach for this issue for the committee to review. The committee discussed certain desired parameters. Mr. Scott Kidner addressed the committee regarding a regulatory approach vs statutory approach. The committee discussed limiting the number of days a non-patient specific medication, medications required for more than 7 days must be prescribed and provided as patient specific compounded medication, unless prohibited by Federal law. Mr. Kidner offered discussion with the DVMA to assist with draft language to provide the Board for review at the next scheduled meeting. He will provide that draft language to Ms. Mast to forward to the Board for the next meeting.

Non Pharmacist Dispensing - tabled until next meeting.

Executive Order 60 – Substantially Related Crimes Listing Review, Ms. Kelly requested that the committee review the crimes listing previously developed through the committee and return next meeting prepared to discuss. Mr. Mangler requested that during the review that the committee considers the relevance of the crime to the profession.

NEW BUSINESS

Telemedicine Pharmacy Regulations Changes – Ms. Kelly provided sample language to the committee. She asked that the members review and come prepared to discuss during the next scheduled meeting.

Delaware Health Information Network (DHIN) Pharmacist Access - tabled until next meeting.

Medicaid/Medicare Notification Regulation 4.1.3 Review - tabled until next meeting.

NABP-NAPLEX Waiting Period Regulation 1.2.4 Change - the committee would like Ms. Kelly to prepare draft legislation changes to be presented to the Board.

PUBLIC COMMENT

None

NEXT SCHEDULED MEETING

The next meeting will be held immediately following the Board of Pharmacy meeting on November 16, 2017, 2016.

ADJOURNMENT

There being no other business before the committee. A motion to adjourn was made by Ms. Patel, seconded by Mr. Galloway. The motion unanimously carried at 1:40 pm.

Respectfully Submitted,



Christine Mast
Administrative Specialist III
Board of Pharmacy